NeuroOne Medical Projects 2026 Revenue of $11.26M, Price Target Implies 183% Upside
NeuroOne Medical expects Q1 revenue of $2.68M and EPS of -$0.04, following a 10.97% revenue beat in Q4. Analysts forecast full-year 2026 revenue of $11.26M (EPS -$0.16) with 2027 revenue estimates raised to $14.87M and average price target implying 183% upside.
1. Q1 2026 Earnings Forecast
NeuroOne Medical plans to report Q1 2026 results on February 17, projecting revenue of $2.68 million and an EPS loss of $0.04. Consensus estimates suggest stable top-line growth after a strong Q4 performance.
2. Full-Year 2026 and 2027 Estimates
Full-year 2026 revenue is expected to reach $11.26 million with an EPS loss of $0.16, while 2027 revenue estimates have been raised from $14.77 million to $14.87 million and earnings estimates improved from a $0.12 loss to a $0.11 loss per share.
3. Historical Q4 Performance
In the quarter ending September 30, 2025, NeuroOne posted revenue of $2.74 million, beating estimates by 10.97%, and reported a $0.04 EPS loss that met expectations; its stock fell 5.49% the day after the release.
4. Analyst Price Targets and Recommendations
Analysts set a one-year average price target of $2.30 (high $3.00, low $1.60), implying an 182.83% upside, while GuruFocus value of $2.05 suggests 152.09% upside. The consensus brokerage rating is 1.5, indicating a 'Buy' recommendation.